Total Payments
$64,060
2024 Payments
$7,037
Companies
15
Transactions
81
Medicare Patients
937
Medicare Billing
$130,985
Payment Breakdown by Category
Consulting$44,521 (69.5%)
Other$12,998 (20.3%)
Travel$3,540 (5.5%)
Food & Beverage$3,001 (4.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $44,521 | 26 | 69.5% |
| Honoraria | $12,998 | 4 | 20.3% |
| Travel and Lodging | $3,540 | 12 | 5.5% |
| Food and Beverage | $3,001 | 39 | 4.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. | $10,600 | 24 | $0 (2020) |
| Curium US LLC | $10,229 | 17 | $0 (2020) |
| Sun Pharmaceutical Industries Inc. | $9,998 | 3 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $8,694 | 10 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $8,125 | 2 | $0 (2023) |
| TerSera Therapeutics LLC | $6,984 | 3 | $0 (2021) |
| Exelixis Inc. | $3,960 | 8 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,960 | 1 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $900.00 | 1 | $0 (2018) |
| Advanced Accelerator Applications | $800.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,037 | 10 | Exelixis Inc. ($3,960) |
| 2023 | $3,900 | 1 | Boehringer Ingelheim International GmbH ($3,900) |
| 2022 | $4,225 | 1 | Boehringer Ingelheim International GmbH ($4,225) |
| 2021 | $7,032 | 4 | TerSera Therapeutics LLC ($6,984) |
| 2020 | $15,223 | 11 | Sun Pharmaceutical Industries Inc. ($9,998) |
| 2019 | $7,380 | 17 | Curium US LLC ($5,229) |
| 2018 | $15,726 | 17 | Novartis Pharmaceuticals Corporation ($8,402) |
| 2017 | $3,537 | 20 | Lexicon Pharmaceuticals, Inc. ($2,365) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,960.00 | General |
| 11/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $132.43 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/27/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $106.32 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $286.77 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $105.13 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $97.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $59.38 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $173.20 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/05/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $117.00 | General |
| Category: Oncology | ||||||
| 03/29/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 09/08/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,225.00 | General |
| 12/15/2021 | TerSera Therapeutics LLC | Xermelo (Drug) | Consulting Fee | Cash or cash equivalent | $1,746.00 | General |
| Category: Oncology | ||||||
| 11/04/2021 | TerSera Therapeutics LLC | Xermelo (Drug) | Consulting Fee | Cash or cash equivalent | $1,746.00 | General |
| Category: Oncology | ||||||
| 09/15/2021 | TerSera Therapeutics LLC | Quzyttir (Drug) | Consulting Fee | Cash or cash equivalent | $3,492.00 | General |
| Category: Acute Care | ||||||
| 09/14/2021 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $48.43 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2020 | Sun Pharmaceutical Industries Inc. | BYNFEZIA PEN (Drug) | Honoraria | Cash or cash equivalent | $4,298.00 | General |
| Category: Oncology | ||||||
| 11/04/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 10/14/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 10/08/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 10/07/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 09/28/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 09/14/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 09/10/2020 | Curium US LLC | Detectnet (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Radioactive diagnostic agent | ||||||
| 06/12/2020 | Sun Pharmaceutical Industries Inc. | BYNFEZIA PEN (Drug) | Honoraria | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 259 | 412 | $107,015 | $35,452 |
| 2022 | 3 | 228 | 382 | $107,263 | $36,337 |
| 2021 | 5 | 246 | 369 | $103,015 | $34,816 |
| 2020 | 4 | 204 | 327 | $90,923 | $24,380 |
Total Patients
937
Total Services
1,490
Medicare Billing
$130,985
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 96 | 169 | $50,556 | $17,240 | 34.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 130 | 210 | $46,206 | $15,468 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $8,833 | $2,385 | 27.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 15 | 15 | $1,419 | $359.10 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 101 | 190 | $58,017 | $20,752 | 35.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 100 | 165 | $37,125 | $11,991 | 32.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $12,121 | $3,595 | 29.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 94 | 170 | $52,012 | $18,602 | 35.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 93 | 120 | $27,000 | $8,750 | 32.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 26 | 26 | $11,534 | $3,714 | 32.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $9,301 | $2,928 | 31.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 13 | 33 | $3,168 | $821.72 | 25.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 111 | 186 | $41,850 | $10,729 | 25.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 51 | 99 | $30,195 | $8,052 | 26.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 31 | 31 | $13,741 | $3,877 | 28.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $5,137 | $1,723 | 33.5% |
About Dr. Lowell Anthony, M.D
Dr. Lowell Anthony, M.D is a Hematology & Oncology healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184622250.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lowell Anthony, M.D has received a total of $64,060 in payments from pharmaceutical and medical device companies, with $7,037 received in 2024. These payments were reported across 81 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($44,521).
As a Medicare-enrolled provider, Anthony has provided services to 937 Medicare beneficiaries, totaling 1,490 services with total Medicare billing of $130,985. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Lexington, KY
- Active Since 07/12/2005
- Last Updated 05/15/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1184622250
Products in Payments
- BYNFEZIA PEN (Drug) $9,998
- SANDOSTATIN LAR (Drug) $8,374
- Xermelo (Drug) $6,082
- Cu64 Dotatate (Drug) $5,212
- Detectnet (Drug) $5,000
- CABOMETYX (Drug) $3,960
- Quzyttir (Drug) $3,492
- Stivarga (Drug) $900.00
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $800.00
- Somatuline Depot (Drug) $290.61
- LUTATHERA (Drug) $165.43
- AFINITOR (Drug) $154.40
- SOMATULINE DEPOT (Drug) $136.67
- SPYGLASS (Device) $135.13
- OPDIVO (Biological) $87.77
- XGEVA (Biological) $86.31
- FOUNDATIONONE (Device) $22.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lexington
Dr. Nicola Jabbour, M.d, M.D
Hematology & Oncology — Payments: $611,455
Hematology & Oncology $611,455
Dr. Zhonglin Hao, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $22,675
Hematology & Oncology $22,675
John Villano
Hematology & Oncology — Payments: $17,051
Hematology & Oncology $17,051
Dr. Jessica Croley, Md, MD
Hematology & Oncology — Payments: $13,189
Hematology & Oncology $13,189
Mr. Russell Eldridge, Md, MD
Hematology & Oncology — Payments: $10,781
Hematology & Oncology $10,781
Reinhold Munker
Hematology & Oncology — Payments: $9,229
Hematology & Oncology $9,229